Loading…
Celularity Inc. is projected to decline to $0.585 by 2027, a -11% move from its current price of $0.6602. CELU is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.6288 | $0.6599 | $0.6925 | -0.05% |
| Aug 6 | $0.616 | $0.6595 | $0.7061 | -0.10% |
| Aug 7 | $0.6063 | $0.6592 | $0.7166 | -0.16% |
| Aug 8 | $0.5982 | $0.6588 | $0.7256 | -0.21% |
| Aug 9 | $0.5912 | $0.6585 | $0.7335 | -0.26% |
| Aug 10 | $0.5848 | $0.6581 | $0.7407 | -0.31% |
| Aug 11 | $0.579 | $0.6578 | $0.7474 | -0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.579 | $0.6578 | $0.7474 | -0.36% |
| Week 2 | $0.5472 | $0.6554 | $0.7851 | -0.72% |
| Week 3 | $0.5235 | $0.653 | $0.8146 | -1.08% |
| Week 4 | $0.5041 | $0.6507 | $0.8399 | -1.44% |
| Week 5 | $0.4874 | $0.6483 | $0.8625 | -1.80% |
| Week 6 | $0.4725 | $0.646 | $0.8831 | -2.16% |
| Week 7 | $0.4592 | $0.6436 | $0.9022 | -2.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Celularity Inc. is a cellular and regenerative medicine company that focuses on addressing aging-related disease using novel therapies. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy.
It also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under LifebankUSA brand. Celularity has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc.
to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Celularity Inc. (CELU) is a healthcare company with a current price of $0.6701, a market capitalization of $19.4M, and a rank of 4876.
The forecast suggests a path from the current level through 2027 and beyond, with 2026: min $0.598, avg $0.6701, max $0.786 (ROI 0, Neutral); 2027: avg $0.6025 (ROI -10.1, Neutral); 2028: avg $0.8151 (ROI 21.6, Bullish); 2030: avg $0.8675 (ROI 29.5, Bullish); 2040: avg $1.27 (ROI 88.9, Bullish); 2050: avg $1.76 (ROI 162.7, Bullish).
In the nearer term the outlook includes a dip in 2027 before resuming an upward trajectory, with stronger gains anticipated in the 2030s and beyond.
A major floor 29.0% below — a decisive break under it would weaken the trend.
The nearest floor, 9.4% below — buyers have tended to step in here.
The nearest ceiling, 22.7% above — a clean break opens room to run.
A major ceiling 112.1% above — clearing it would confirm fresh momentum.
Key CELU support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CELU market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.6992 | Sell | $0.6875 | Sell |
| MA 10 | $0.7376 | Sell | $0.7149 | Sell |
| MA 20 | $0.7479 | Sell | $0.7314 | Sell |
| MA 50 | $0.78 | Sell | $0.7937 | Sell |
| MA 100 | $0.9578 | Sell | $0.9426 | Sell |
| MA 200 | $1.24 | Sell | $1.24 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.66 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -246.32 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -18.59 | Sell |
| Bollinger %B (20,2) | -0.17 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.15 | Sell |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 20.64 | Buy |
| Momentum (10) | -0.14 | Sell |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 0.65 | Buy |
| ADX (14) | 13.11 | Neutral |
| ATR (14) | 0.03 | Info |
Near-term technical picture: sentiment is BEARISH; RSI14 is 40. The 50-day simple moving average (SMA50) is $0.7858 and the 200-day simple moving average (SMA200) is $1.26. The stock sits on a near-term support of $0.598 and resistance of $0.81, with a 30-day range of $0.4844 to $0.9269.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.598 | $0.6602 | $0.7727 | 0% | Neutral | |
| $0.4343 | $0.585 | $0.8493 | -11% | Neutral | |
| $0.5615 | $0.7988 | $1.23 | +21% | Bullish | |
| $0.5501 | $0.8194 | $1.32 | +24% | Bullish | |
| $0.5434 | $0.8436 | $1.41 | +28% | Bullish | |
| $0.5353 | $0.8636 | $1.50 | +31% | Bullish | |
| $0.4253 | $0.7116 | $1.27 | +8% | Neutral | |
| $0.4457 | $0.7722 | $1.41 | +17% | Neutral | |
| $0.51 | $0.9138 | $1.71 | +38% | Bullish | |
| $0.5601 | $1.04 | $1.99 | +57% | Bullish | |
| $0.57 | $1.23 | $2.58 | +87% | Bullish | |
| $0.7707 | $1.71 | $3.94 | +159% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.598 | $0.6602 | $0.763 | +0.00% |
| September 2026 | $0.4998 | $0.6041 | $0.7598 | -8.49% |
| October 2026 | $0.5145 | $0.6297 | $0.8067 | +4.23% |
| November 2026 | $0.4998 | $0.618 | $0.8035 | -1.85% |
| December 2026 | $0.4699 | $0.5865 | $0.7727 | -5.10% |
Click any year to see its month-by-month CELU forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CELU to range from $0.598 to $0.7727 through 2026. The $0.6602 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CELU price prediction for 2027 points to an average of $0.585 (low $0.4343, high $0.8493) — a potential decline of -11% on today's $0.6602. A consolidation phase looks the most probable path here.
In 2028, CELU is projected to trade between $0.5615 and $1.23, averaging $0.7988 — a potential gain of +21% from today's $0.6602. That is up +37% on the projected 2027 average. Momentum favours further upside here.
Celularity Inc.'s 2029 outlook centres on $0.8194, within a $0.5501 to $1.32 range. That is up +3% on the projected 2028 average. That marks a +24% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, CELU could reach as high as $1.41, with a base case around $0.8436 and support toward $0.5434 — roughly +28% from $0.6602. Momentum favours further upside here.
Expect CELU to range from $0.5353 to $1.50 through 2031. The $0.8636 average target implies a +31% move from current prices. That is up +2% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The CELU price prediction for 2032 points to an average of $0.7116 (low $0.4253, high $1.27) — a potential gain of +8% on today's $0.6602. Price action looks broadly range-bound.
In 2033, CELU is projected to trade between $0.4457 and $1.41, averaging $0.7722 — a potential gain of +17% from today's $0.6602. That is up +9% on the projected 2032 average. A consolidation phase looks the most probable path here.
Celularity Inc.'s 2034 outlook centres on $0.9138, within a $0.51 to $1.71 range. That is up +18% on the projected 2033 average. That marks a +38% change versus current levels. Momentum favours further upside here.
By 2035, CELU could reach as high as $1.99, with a base case around $1.04 and support toward $0.5601 — roughly +57% from $0.6602. Buyers look set to stay in control over this stretch.
Expect CELU to range from $0.57 to $2.58 through 2040. The $1.23 average target implies a +87% move from current prices. That is up +19% on the projected 2035 average. Momentum favours further upside here.
The CELU price prediction for 2050 points to an average of $1.71 (low $0.7707, high $3.94) — a potential gain of +159% on today's $0.6602. Buyers look set to stay in control over this stretch.
Investing $1,000 in CELU today (≈ 1,514.692517 CELU) could be worth
$2,594.02
+$1,594.02 (+159%) by 2050 · US Dollar
Based on the average projected CELU price of $1.71 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CELUwould be worth at today's price.
$1,000 invested in CELU on Jul 31, 2025 (≈ 304.878051 CELU) would be worth
$201.28
-$798.72 (-79.9%) today · 0.20× · US Dollar
Based on a CELU entry price of $3.28 vs. today's $0.6602.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.75 | $880.27 | -12.0% |
| 1 month ago | $0.604 | $1,093.05 | +9.3% |
| 3 months ago | $0.957 | $689.86 | -31.0% |
| 6 months ago | $1.26 | $523.97 | -47.6% |
| 1 year ago | $3.28 | $201.28 | -79.9% |
| All time (5.0y) ago | $80 | $8.25 | -99.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CELU forecast.
Our base-case forecast reaches $1.30 around 2050.
Implied market cap at $1.30: $37.63M
The multi-year forecast shows a bullish trajectory in the later years, with a sequence of bullish years starting in 2028 and continuing through 2031, and continuing into the 2030s and beyond. The forecasted averages and ROIs include: 2026 avg $0.6701, ROI 0 (Neutral); 2027 avg $0.6025, ROI -10.1 (Neutral); 2028 avg $0.8151, ROI 21.6 (Bullish); 2029 avg $0.8374, ROI 25 (Bullish); 2030 avg $0.8675, ROI 29.5 (Bullish); 2031 avg $0.8796, ROI 31.3 (Bullish); 2032 avg $0.7229, ROI 7.9 (Neutral); 2033 avg $0.7931, ROI 18.4 (Neutral); 2034 avg $0.9384, ROI 40 (Bullish); 2035 avg $1.07, ROI 59.3 (Bullish); 2040 avg $1.27, ROI 88.9 (Bullish); 2050 avg $1.76, ROI 162.7 (Bullish).
These are estimates, not guarantees, and depend on multiple factors that can affect the stock’s performance over time.
Tap a question to reveal the answer.
Avg $0.8675; max $1.46; min $0.5545; ROI 29.5%; sentiment BULLISH.
Forecasts show a neutral stance in 2026-2027 followed by bullish gains, with avg price rising to $1.27 by 2040 and $1.76 by 2050, and maxes up to $4.05 by 2050. ROI peaks at 162.7% by 2050. These are estimates, not guarantees.
Yes—the max forecast by 2050 is $4.05, with ROI of 162.7%.
Current price is $0.6701 and market cap is $19.4M.
Bearish sentiment with RSI 14 at 40. 30-day range is $0.4844 to $0.9269; near-term support is $0.598 and resistance is $0.81.
Celularity Inc. Community Discussion
0Share your Celularity Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.